Basic understanding of current classification and management of retinoblastoma

Current Opinion in Ophthalmology

Volumn 17, Issue 3, 2006, Pages 228-234

  Shields, Carol L ^a   Shields, Jerry A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer; Chemoreduction; Chemotherapy; Eye; Plaque radiotherapy; Retinoblastoma; Tumor

Indexed keywords

CARBOPLATIN; ETOPOSIDE; POLY(METHYL METHACRYLATE); POLYETHYLENE; ROSEOLIC ACID; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CRYOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENUCLEATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; LASER COAGULATION; METASTASIS; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; ORBIT IMPLANT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RELIABILITY; RETINOBLASTOMA; REVIEW; SUBRETINAL FLUID; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CRYOTHERAPY; EYE ENUCLEATION; HUMANS; LASER SURGERY; LASER THERAPY; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 33748137236     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000193079.55240.18     Document Type: Review

References (31)

1. Shields JA, Shields CL. Management and prognosis of retinoblastoma. In: Intraocular tumors: a text and atlas. Philadelphia: WB Saunders; 1992. pp. 377-392.
2. Shields JA, Shields CL. Retinoblastoma. In: Shields JA, Shields CL, editors. Atlas of intraocular tumors. Philadelphia: Lippincott Williams Wilkins; 1999. pp. 207-232.
3. Rodrigues KE, Latorre Mdo R, de Camargo B. Delayed diagnosis in retinoblastoma. J Pediatr (Rio J) 2004; 80:511-516.
4. Abramson DH, Melson MR, Dunkel IJ, Frank CM. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 2001; 108:1868-1876.
5. Nichols KE, Houseknecht MD, Godmilow L, et al. Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RB1 gene. Hum Mutat 2005; 25:566-574. Germline RB1 mutations were identified in 77 out of 85 bilateral retinoblastoma patients (91%), seven out of 10 familial unilateral (70%), and six out of 85 unilateral patients with no family history of retinoblastoma (7%). Mutations included 36 novel alterations spanning the entire RB1 gene.
6. Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma: metastatic potential and clinical risk factors. Cancer 1994; 1:692-698.
7. Shields CL, Shields JA, Baez KA, et al. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol 1993; 77:544-548.
8. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002; 120:923-931.
9. Kivela T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999; 17:1829-1837.
10. De Potter P, Shields CL, Shields JA. Clinical variations of trilateral retinoblastoma: a report of 13 cases. J Pediatr Ophthalmol Strabismus 1994; 31:26-31.
11. Shields CL, Meadows AT, Shields JA, et al. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 2001; 119:1269-1272.
12. Karatza E, Shields CL, Flanders AE, et al. Pineal cyst simulating pinealoblastoma in 11 children with retinoblastoma. Arch Ophthalmol 2006 (in press).
13. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 1988; 95:1583-1587.
14. Wong FL, Boice JD Jr. Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA 1997; 278:1262-1267.
15. Shields CL, Mashayekhi A, Demirci H, et al. A practical approach to management of retinoblastoma. Arch Ophthalmol 2004; 122:729-735. There were 158 eyes with retinoblastoma treated with chemoreduction. The eyes were grouped based on a simple classification: group 1, tumor only; group 2, tumor plus subretinal fluid; group 3, tumor plus focal seeds; group 4, tumor plus diffuse seeds; and group 5, neovascular glaucoma or invasive retinoblastoma. The classification system predicted success with chemoreduction as there was 100% success for group 1, 91% for group 2, 59% for group 3, and 12% for group 4 (group 5 was always managed by primary enucleation).
16. Murphree AL. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005; 200:41-53, (viii).
17. Shields CL, Au AK, Czyz C, et al. The International Classification of Retinoblastoma (ICRB) predicts chemoreduction success. Presented at the International Society of Ocular Oncology; 1-5 September 2005; Whistler, Canada and the American Academy of Ophthalmology 14-16 October 2005.
18. Shields CL, Honavar S, Shields JA, et al. Vitrectomy in eyes with unsuspected retinoblastoma. Ophthalmology 2000; 107:2250-2255.
19. Epstein J, Shields CL, Shields JA. Trends in the management of retinoblastoma; Evaluation of 1,196 consecutive eyes during 1974-2001. J Pediatr Ophthalmol Strab 2003; 40:196-203.
20. Shields CL, Meadows AT, Leahey AM, Shields JA. Continuing challenges in the management of retinoblastoma with chemoreduction. Retina 2004; 24:849-862.
21. Shields CL, Gorry T, Shields JA. Outcome of eyes with unilateral sporadic retinoblastoma based on initial external findings by the family and pediatrician. J Ped Ophthalmol Strab 2004; 41:143-149.
22. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002; 133:657-664.
23. Shields CL, Mashayekhi A, Cater J, et al. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 2004; 138:329-337.
24. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999; 106:1947-1950.
25. Shields CL, Sun H, Mashayekhi A, et al. Plaque radiotherapy following chemoreduction for retinoblastoma. Presented at the International Society of Ocular Oncology; 1-5 September 2005; Whistler, Canada and at the World Congress of Ophthalmology; March 2006; Sao Paolo, Brazil.
26. Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol 2004; 9:1-6.
27. Hurwitz MY, Marcus KT, Chevez-Barrios P, et al. Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther 1999; 10:441-448.
28. Shields CL, Shelil A, Cater J, et al. Development of new retinoblastomas following six cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 2003; 131:1571-1576.
29. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for retinoblastoma: Long term tumor control and treatment complications in 208 tumors. Ophthalmology 2001; 108:2116-2121.
30. Shields CL, Shields JA, DePotter P, Singh AD. Lack of complications of the hydroxyapatite orbital implant in 250 consecutive cases. Trans Am Ophthalmol Soc 1993; 91:177-189.
31. Shields CL, Au A, Mashayekhi A, et al. Hydroxyapatite orbital implant in children: analysis of 374 cases. Presented as a poster at the American Society of Ophthalmic Plastic Surgery; 14-15 October 2005.